Evaluation of the effectiveness of letrozole in EP treatment

Comparison evaluation of letrozol metoretoxate treatment in patients with ectopic pregnancy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220411054497N1

Enrollment

Registered

2022-10-03

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic Pregnancy. Ectopic pregnancy, unspecified

Interventions

Intervention 1: The intervention group: includes a group of 24 people receiving letrozole for the treatment of EP, after explaining the benefits and side effects of both treatment methods and obtainin

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Absence of active intra-abdominal bleeding Adnexal mass below four centimeters The person is healthy in terms of liver and kidney disease B-HCG levels should be less than 5000 The patient should not breastfeed

Exclusion criteria

Exclusion criteria: If the patient is a candidate for surgery If the patient does not consent to participate in the study

Design outcomes

Primary

Measure	Time frame
B-HCG. Timepoint: 0 day fourth day and seventh day. Method of measurement: Blood test and B-HCG check request.;Duration of zeroing of B-HCG in the two groups of letrozole and methotrexate. Timepoint: From day one of B-HCG assay until the B-HCG marker is zero. Method of measurement: Blood test and B-HCG check request.	—

Secondary

Measure	Time frame
Hbg. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;WBC. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;Platelets. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;LFT. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Blood test and blood biochemistry check.;BUN. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Blood test and blood biochemistry check.	—

Measure

Time frame

Hbg. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;WBC. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;Platelets. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Taking blood tests and checking CBC.;LFT. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Blood test and blood biochemistry check.;BUN. Timepoint: The first day of referral, the fourth day and the seventh day and then weekly until the BHCG is zero. Method of measurement: Blood test and blood biochemistry check.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSanaz Maleki

Qazvin University of Medical Sciences

sanazmlk97@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026